Drug intelligence / Profile preview

BR3409-2

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR3409-2 is an experimental small molecule drug developed by Boryung Corp. It is being investigated as part of a combination therapy (with BR3409 and BR3409-1) for the treatment of type 2 diabetes mellitus. The drug has been evaluated in Phase 1 clinical trials to assess its pharmacokinetics and safety, both alone and in co-administration with related compounds, in healthy volunteers under fasting and fed conditions. The precise mechanism of action, molecular target(s), and detailed pharmacological profile have not been publicly disclosed as of June 2025[1][2][5].

Beyond the preview

Go deeper on BR3409-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR3409-2.

Explore the full profile